Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Eva Steiness

Dr. Bjarne Due Larsen

Lars Hellerung Christiansen

Zealand Pharma A/S

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

H. Lundbeck A/S

MannKind Corporation develops and commercializes innovative therapeutic products and devices for people living with endocrine and orphan lung diseases.

MannKind Corporation

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a Danish biotechnology company on a mission to change lives with next generation peptide medicines. In our effort to reach our goals bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other. This has led to more than 10 drug candidates invented by Zealand having advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Additionally, the portfolio includes clinical license collaboration with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals. Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn or Twitter @ZealandPharma.

Metric
Company Name	Zealand Pharma A/S	Ardelyx, Inc.	H. Lundbeck A/S	MannKind Corporation
Symbol	ZEAL	ARDX	LUN
MSH ID	COM:ZEALANDPHARMA	COM:ARDELYX	COM:LUNDBECK	COM:VALERITAS
Market	STOCKS	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Drug Manufacturers - Specialty & Generic	Biotechnology
Country	DK	US	DK	US
Stage		Debt
Employee Count	270	267	5.35K
Website	zealandpharma.com	ardelyx.com	lundbeck.com	valeritas.com
LinkedIn	zealand-pharma
Founders

Metric
Market Cap	9.31B	1.30B
Enterprise Value
Monthly Web Traffic		33.50K
Web Traffic Growth		2.80
Valuation
Raised Capital		20M

Metric
Revenue	48.54M	124.46M	2.82B
Revenue (LTM)
Revenue (NTM)
Gross Profit	41.82M	106.66M	2.18B
EBITDA	-75.47M	-55.35M	720.26M
Operating Income	-79.48M	-63.28M	452.47M
Net Income	-99.66M	-66.07M	324.30M
EPS	-1.76	-0.30	0.33
Diluted EPS	-1.76	-0.30	0.33
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.90	0.86	0.78
Operating Profit Margin	-1.64	-0.28	0.17
EBITDA Margin	-1.55	-0.44	0.26
Net Profit Margin	-1.93	-0.31	0.12
Return on Equity	-0.18	-0.40	0.11
Return on Assets	-0.07	-0.19	0.07
Return on Capital Employed	-0.07	-0.21	0.11

COM:ZEALANDPHARMA

Zealand Pharma A/S

Last Close

726.50

25/11 09:40

Market Cap

65.70B

Beta: -

Volume Today

40.84K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-37.72	-74.58	26.03
P/B Ratio	15.78	10.37	1.88
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	195.79	14.47	1.89
EV Multiple	-78.33	-20.25	9.97

Metric
Days Sales Outstanding		117.61
Days Payables Outstanding	19.32K	185.33	391.61
Days Inventory Outstanding	29.92	264.91	368.68
Operating Cycle	218.69	329.52	448.16
Cash Conversion Cycle	-446.88	100.07	101.40
Asset Turnover	0.11	0.61	0.53

Metric
Operating Cash Flow	-60.28M	-89.72M	577.80M
Free Cash Flow	-63.65M	-90.06M	506.85M
Cash Flow to Debt	-1.57	-0.77	1.23
Operating Cash Flow/Sales	-1.24	-0.41	0.23
Free Cash Flow Yield	-0.03	-0.03

Metric
Cash & Equivalents	63.63M	21.47M	709.50M
Accounts Receivable	-2.63M	-14.30M	-23.65M
Inventory	1.12M	12.45M	626.94M
Goodwill			779.88M
Debt to Capitalization	0.09	0.41	0.23
Debt to Assets	0.05	0.12	0.15
Current Ratio	7.63	5.54	0.98
Quick Ratio	35.57	4.36	1.32

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.08	0.09
R&D to Revenue	1.91	0.26	0.23
SG&A to Revenue	0.67	0.15	0.06